DCK and pancreatic neoplasm: Clinical studies have shown that the DCK expression level in pancreatic cancer tissue is a reliable prognostic indicator of PFS, suggesting that DCK is a good biomarker of gemcitabine sensitivity for pancreatic cancer patients treated with gemcitabine[79,80].